In patients with FOP, ALK2 has a mutation that gives it a novel and abnormal ability to initiate pro-osteogenic Smad1/5/8 signaling upon binding by activin A. This effectively allows ALK2-expressing cells to misinterpret activin A as a BMP. Here, SMAD1 is linked to fibrodysplasia ossificans progressiva.